J&J
This article was originally published in The Tan Sheet
Executive Summary
Alza shareholders approve merger agreement June 21; deal closes following day. Alza shareholders will receive .98 shares of J&J common stock for each Alza share in transaction estimated at $10.5 bil. (1"The Tan Sheet" April 2, In Brief)
You may also be interested in...
J&J/Alza acquisition
Palo Alto, Calif.-based Alza will retain its name and management as a free-standing J&J company and will continue to develop new products for other pharmaceutical customers based on its advanced drug delivery technologies under the terms of a stock-for-stock merger transaction with J&J estimated at $10.5 bil. Alza developed technology used in NicoDerm CQ transdermal patch licensed by GlaxoSmithKline and also created 24-hour time-release pseudoephedrine technology employed by various OTC cough/cold remedies, including Warner-Lambert Consumer Group's Sudafed 24 Hour. Abbott Labs attempted to acquire Alza in 1999, but deal fell through because firms could not agree on divestiture plan with FTC. J&J agreement is anticipated to close early in third quarter
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands